Mitsubishi Tanabe Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MITSUBISHI TANABE, and what generic alternatives to MITSUBISHI TANABE drugs are available?
MITSUBISHI TANABE has two approved drugs.
There are three US patents protecting MITSUBISHI TANABE drugs.
There are fifteen patent family members on MITSUBISHI TANABE drugs in thirteen countries.
Summary for Mitsubishi Tanabe
| International Patents: | 15 |
| US Patents: | 3 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Mitsubishi Tanabe
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-002 | Nov 15, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | 11,478,450 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | 11,241,416 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-001 | May 5, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | 10,987,341 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mitsubishi Tanabe
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-001 | May 5, 2017 | 6,933,310 | ⤷ Try a Trial |
| Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-002 | Nov 15, 2018 | 6,933,310 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Mitsubishi Tanabe Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20210087490 | ⤷ Try a Trial |
| Japan | WO2020091036 | ⤷ Try a Trial |
| Australia | 2019369843 | ⤷ Try a Trial |
| Japan | 7274502 | ⤷ Try a Trial |
| Taiwan | 202031256 | ⤷ Try a Trial |
| European Patent Office | 3875085 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
